219 related articles for article (PubMed ID: 33091845)
1. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
Lek SM; Li K; Tan QX; Shannon NB; Ng WH; Hendrikson J; Tan JWS; Lim HJ; Chen Y; Koh KKN; Skanthakumar T; Kwang XL; Chong FT; Leong HS; Tay G; Putri NE; Lim TKH; Hwang JSG; Ang MK; Tan DSW; Tan NC; Tan HK; Kon OL; Soo KC; Iyer NG; Ong CJ
Oral Oncol; 2020 Dec; 111():105035. PubMed ID: 33091845
[TBL] [Abstract][Full Text] [Related]
2. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.
Li B; Zhu J; Meng L
Mol Med Rep; 2019 Feb; 19(2):877-884. PubMed ID: 30535476
[TBL] [Abstract][Full Text] [Related]
3. Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior.
Chien CY; Tsai HT; Su LJ; Chuang HC; Shiu LY; Huang CC; Fang FM; Yu CC; Su HT; Chen CH
Oncotarget; 2014 Apr; 5(8):2243-62. PubMed ID: 24810160
[TBL] [Abstract][Full Text] [Related]
4. Identification of AURKA as a Biomarker Associated with Cuproptosis and Ferroptosis in HNSCC.
Jia X; Tian J; Fu Y; Wang Y; Yang Y; Zhang M; Yang C; Liu Y
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673957
[TBL] [Abstract][Full Text] [Related]
5. Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.
Wang Y; Liu P; Zhang Z; Wang J; Cheng Z; Fan C
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34505628
[TBL] [Abstract][Full Text] [Related]
6. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
[TBL] [Abstract][Full Text] [Related]
8. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.
Mazumdar A; Henderson YC; El-Naggar AK; Sen S; Clayman GL
Head Neck; 2009 May; 31(5):625-34. PubMed ID: 19107951
[TBL] [Abstract][Full Text] [Related]
10. Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma.
Shah PA; Sambandam V; Fernandez AM; Zhao H; Mazumdar T; Shen L; Wang Q; Ahmed KM; Ghosh S; Frederick MJ; Wang J; Johnson FM
Cancer Res; 2022 Dec; 82(23):4444-4456. PubMed ID: 36169922
[TBL] [Abstract][Full Text] [Related]
11. Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC.
Li J; Yan T; Wu X; Ke X; Li X; Zhu Y; Yang J; Li Z
BMC Cancer; 2021 Nov; 21(1):1205. PubMed ID: 34772357
[TBL] [Abstract][Full Text] [Related]
12. The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.
Pickhard A; Siegl M; Baumann A; Huhn M; Wirth M; Reiter R; Rudelius M; Piontek G; Brockhoff G
Oncotarget; 2014 Jul; 5(14):5428-38. PubMed ID: 24980817
[TBL] [Abstract][Full Text] [Related]
13. ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β-catenin pathway.
Wang R; Liu X; Li X; Qian M; Yang X; Jiang Q; Wang Y; Liu H; Chen J; Wang X; Gong L
Mol Carcinog; 2024 Jun; 63(6):1079-1091. PubMed ID: 38426809
[TBL] [Abstract][Full Text] [Related]
14. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
[TBL] [Abstract][Full Text] [Related]
15. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
[TBL] [Abstract][Full Text] [Related]
16. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
17. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
[TBL] [Abstract][Full Text] [Related]
18. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
19. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]